Topic: Boehringer Ingelheim Gmbh
Marcus Thomas' latest new-business win is a real shot in the arm. Ohio-based Bedford Laboratories after a review has named the independent in ...
Sub-analysis shows no significant interaction between trial centers' time in therapeutic range and stroke with either dose of dabigatran etexilate...
Impulse control disorders (ICDs) are fairly common in people with Parkinson's disease and are associated with several clinical and demographic...
from USA Today. . - The first pill designed to boost the female sex drive failed to make a significant impact on libido in two studies, federal...
FDA scientists says the first pill designed to increase female libido failed in 2 studiesUNSTIMULATING RESPONSE: The Food and Drug Administration says a drug from Boehringer Ingelheim designed to stimulate female libido fell short in two studies.PINK PILL
CHICAGO (Reuters) - A widely used class of blood pressure drugs may slightly increase the risk of cancer, U.S. researchers said on Sunday, and they are calling on U.S. regulators to take a closer look.They said an analysis of available ...
<div id="subtitle">German drugmaker, state of Wisconsin reach $7.75M settlement on suit alleging Medicaid fraudA German-based pharmaceutical company has agreed to pay $7.75 million to settle allegations that four of its subsidiaries committed price
German drugmaker Boehringer Ingelheim and Vitae Pharmaceuticals say they are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.The deal could be worth roughly $250 million to Vitae, a
Video Gallery
-
Boehringer Ingelheim - faces400
Boehringer Ingelheim - faces4002008-10-27 -
Boehringer Ingelheim - Hope in battle against ...
Boehringer Ingelheim - Hope in battle against AIDS2008-10-27 -
Boehringer Ingelheim Spiriva Safety Data
Dr Marc Decramer, UPLIFT lead investigator and Professor of Medicine ...2009-09-17
